Lipoprotein lipase disturbances induced by uremia and hemodialysis

Seminars in Dialysis

Volumn 22, Issue 4, 2009, Pages 442-444

  Stegmayr, Bernd ^a,c   Olivecrona, Thomas ^b   Olivecrona, Gunilla ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c Medicinkliniken   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN LIPASE;

ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; ENZYMOLOGY; HUMAN; RENAL REPLACEMENT THERAPY; UREMIA;

CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEIN LIPASE; RENAL DIALYSIS; UREMIA;

EID: 69249140609     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2009.00597.x     Document Type: Article

References (49)

1. Schon S, Ekberg H, Wikstrom B, Oden A, Ahlmen J : Renal replacement therapy in Sweden. Scand J Urol Nephrol 38 : 332 339, 2004
2. Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R : The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 28 : 478 483, 2007
3. Stegmayr BG : Ultrafiltration and dry weight-what are the cardiovascular effects? Artif Organs 27 : 227 229, 2003
4. Stegmayr BG, Brannstrom M, Bucht S, Dimeny E, Ekspong A, Granroth B, Grontoft KC, Hadimeri H, Holmberg B, Ingman B, Isaksson B, Johansson G, Lindberger K, Lundberg L, Lundstrom O, Mikaelsson L, Mortzell M, Olausson E, Persson B, Svensson L, Wikdahl AM : Minimized weight gain between hemodialysis contributes to a reduced risk of death. Int J Artif Organs 29 : 675 680, 2006
5. Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C, Bommer J, Akiba T, Mapes DL, Young EW, Port FK : Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 69 : 1222 1228, 2006
6. Stenvinkel P, Alvestrand A : Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 15 : 329 337, 2002
7. Sterky E, Stegmayr BG : Elderly patients on haemodialysis have 50% less functional capacity than gender- and age-matched healthy subjects. Scand J Urol Nephrol 39 : 423 430, 2005
8. Gil HW, Yang JO, Lee EY, Lee EM, Choi JS, Hong SY : The effect of dialysis membrane flux on amino acid loss in hemodialysis patients. J Korean Med Sci 22 : 598 603, 2007
9. Burrowes JD, Larive B, Chertow GM, Cockram DB, Dwyer JT, Greene T, Kusek JW, Leung J, Rocco MV : Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. Nephrol Dial Transplant 20 : 2765 2774, 2005
10. Bossola M, Tazza L, Giungi S, Luciani G : Anorexia in hemodialysis patients: an update. Kidney Int 70 : 417 422, 2006
11. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML : Uremic toxicity: present state of the art. Int J Artif Organs 24 : 695 725, 2001
12. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W : Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 63 : 1934 1943, 2003
13. Preiss-Landl K, Zimmermann R, Hammerle G, Zechner R : Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr Opin Lipidol 13 : 471 481, 2002
14. Olivecrona G, Olivecrona T : Clearance of artificial triacylglycerol particles. Curr Opin Clin Nutr Metab Care 1 : 143 151, 1998
15. Mead JR, Ramji DP : The pivotal role of lipoprotein lipase in atherosclerosis. Cardiovasc Res 55 : 261 269, 2002
16. Twickler T, Dallinga-Thie GM, Chapman MJ, Cohn JS : Remnant lipoproteins and atherosclerosis. Curr Atheroscler Rep 7 : 140 147, 2005
17. Fielding BA, Frayn KN : Lipoprotein lipase and the disposition of dietary fatty acids. Br J Nutr 80 : 495 502, 1998
18. Olivecrona T, Olivecrona G : Lipoprotein and hepatic lipase in lipoprotein metabolism. In : Breckenridge DJ (ed). Lipoproteins in Health and Disease. London : Arnold, 1999 223 246.
19. Bagdade JD : Uremic lipemia. An unrecognized abnormality in triglyceride production and removal. Arch Intern Med 126 : 875 881, 1970
20. Arnadottir M, Thysell H, Dallongeville J, Fruchart JC, Nilsson-Ehle P : Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int 48 : 779 784, 1995
21. Shearer GC, Kaysen GA : Endothelial bound lipoprotein lipase (LpL) depletion in hypoalbuminemia results from decreased endothelial binding, not decreased secretion. Kidney Int 70 : 647 653, 2006
22. Wessel-Aas T, Blomhoff JP, Wideroe TE, Wirum E, Nilsen T : The effect of systemic heparinization on plasma lipoproteins and toxicity in patients on hemodialysis and continuous ambulatory peritoneal dialysis. Acta Med Scand 216 : 85 92, 1984
23. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H : Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 41 : 1653 1661, 1992
24. Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG : Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients. Scand J Clin Lab Invest 63 : 45 53, 2003
25. Nasstrom B, Stegmayr B, Olivecrona G, Olivecrona T : Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme. BMC Nephrol 5 : 17, 2004
26. Nasstrom B, Stegmayr B, Gupta J, Olivecrona G, Olivecrona T : A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. Nephrol Dial Transplant 20 : 1172 1179, 2005
27. Näsström B : Lipoprotein Lipase in Hemodialysis Patients and Health Controls - Effects of Heparin. Sweden : Umea University, 2004.
28. Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG : Lipoprotein lipase during continuous heparin infusion: tissue stores become partially depleted. J Lab Clin Med 138 : 206 213, 2001
29. Nasstrom B, Stegmayr BG, Olivecrona G, Olivecrona T : Lower plasma levels of lipoprotein lipase after infusion of low molecular weight heparin than after administration of conventional heparin indicate more rapid catabolism of the enzyme. J Lab Clin Med 142 : 90 99, 2003
30. Murase T, Cattran DC, Rubenstein B, Steiner G : Inhibition of lipoprotein lipase by uremic plasma, a possible cause of hypertriglyceridemia. Metabolism 24 : 1279 1286, 1975
31. Cheung AK, Parker CJ, Ren K, Iverius PH : Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Kidney Int 49 : 1360 1371, 1996
32. Heuck CC, Ritz E : Does parathyroid hormone play a role in lipid metabolism? Contrib Nephrol 20 : 118 128, 1980
33. Akmal M, Kasim SE, Soliman AR, Massry SG : Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 37 : 854 858, 1990
34. Vaziri ND, Wang XQ, Liang K : Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol 1997 273 (6 Pt 2 F925 F930.
35. Querfeld U, Hoffmann MM, Klaus G, Eifinger F, Ackerschott M, Michalk D, Kern PA : Antagonistic effects of vitamin D and parathyroid hormone on lipoprotein lipase in cultured adipocytes. J Am Soc Nephrol 10 : 2158 2164, 1999
36. Zhang L, Wu G, Tate CG, Lookene A, Olivecrona G : Calreticulin promotes folding/dimerization of human lipoprotein lipase expressed in insect cells (sf21). J Biol Chem 278 : 29344 29351, 2003
37. Zhang L, Lookene A, Wu G, Olivecrona G : Calcium triggers folding of lipoprotein lipase into active dimers. J Biol Chem 280 : 42580 42591, 2005
38. Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG : Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest 97 : 2167 2173, 1996
39. Druml W, Zechner R, Magometschnigg D, Lenz K, Kleinberger G, Laggner A, Kostner G : Post-heparin lipolytic activity in acute renal failure. Clin Nephrol 23 : 289 293, 1985 (Pubitemid 15059839)
40. Vaziri ND : Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290 : F262 F272, 2006
41. Attman PO, Samuelsson O, Alaupovic P : Lipoprotein metabolism and renal failure. Am J Kidney Dis 21 : 573 592, 1993
42. Liang K, Oveisi F, Vaziri ND : Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int 53 : 626 630, 1998
43. Bey L, Hamilton MT : Suppression of skeletal muscle lipoprotein lipase activity during physical inactivity: a molecular reason to maintain daily low-intensity activity. J Physiol 2003 551 (Pt 2 673 682.
44. Farese RV Jr., Yost TJ, Eckel RH : Tissue-specific regulation of lipoprotein lipase activity by insulin/glucose in normal-weight humans. Metabolism 40 : 214 216, 1991
45. Saland JM, Ginsberg HN : Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol 22 : 1095 1112, 2007
46. Takenaka T, Kanno Y, Ohno Y, Suzuki H : Key role of insulin resistance in vascular injury among hemodialysis patients. Metabolism 56 : 153 159, 2007
47. Krogh-Madsen R, Plomgaard P, Akerstrom T, Moller K, Schmitz O, Pedersen BK : Effect of short-term intralipid infusion on the immune response during low-dose endotoxemia in humans. Am J Physiol Endocrinol Metab 294 : E371 E379, 2008
48. Semb H, Peterson J, Tavernier J, Olivecrona T : Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol Chem 262 : 8390 8394, 1987
49. Wu G, Brouckaert P, Olivecrona T : Rapid downregulation of adipose tissue lipoprotein lipase activity on food deprivation: evidence that TNF-alpha is involved. Am J Physiol Endocrinol Metab 286 : E711 E717, 2004